Kairos Pharma

KAPA

Biotechnology · Healthcare

Price

$0.31

-0.03 (-8.80%)

Market Cap

$6.6M

Exchange

New York Stock Exchange American

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+43.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 12.8M (2021) → 18.4M (2025)

Kairos Pharma is a small clinical-stage biotechnology company focused on developing drugs to treat cancer. It does not yet sell any approved products. Its pipeline targets solid tumors and other cancers, with the goal of eventually selling treatments to hospitals, oncologists, and cancer patients.

Because it has no approved drugs, Kairos generates essentially no revenue today. The company funds its operations through stock offerings and other financing, which is common for early-stage biotech firms. It operates primarily in the United States and has a very small market presence. The central risk is straightforward: if its drug candidates fail in clinical trials or cannot win regulatory approval from the FDA, the company may struggle to survive without continuously raising new capital from investors.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+1.0% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$2M/ year

↑ Rising (+416% vs prior year)

R&D investment increasing — building for the future

Insider Activity

58.1%ownership

Insiders own a meaningful stake in the company

Cash Runway

~11 months

$4M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Kairos Pharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-30.4%

Weak — -30.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial